Pharmacy Outlook 2026 report: Where does your pharmacy stand?
Powered by Cencora's Accelerate Pharmacy Solutions, the Pharmacy Outlook 2026 draws on proprietary survey data from more than 100 health system pharmacy leaders navigating payer restrictions, specialty leakage, infusion expansion, and evolving regulatory pressures.
The report offers benchmarks across specialty pharmacy, 340B, infusion services, financial optimization, supply chain, and cell and gene therapy, along with expert analysis on where programs are maturing, where gaps remain, and what's working for organizations that are pulling ahead.
A few findings from this year's research:
The report offers benchmarks across specialty pharmacy, 340B, infusion services, financial optimization, supply chain, and cell and gene therapy, along with expert analysis on where programs are maturing, where gaps remain, and what's working for organizations that are pulling ahead.
A few findings from this year's research:
- Half of specialty patients are filling prescriptions externally—even at programs with mature operations.
- Over 1 in 4 health systems plan to launch home infusion within 3 years. The average time-to-therapy is 5.7 days, nearly double the 3-day target for optimized programs.
- 340B optimization is the #1 financial priority for 2026, even as manufacturer restrictions and compliance pressures increase.
Download the report to benchmark your program and identify where to focus next.
Please fill out the form to download the whitepaper.